Levofloxacin-13C,d3 (CAS: 1261398-33-7), a premium pharmaceutical research compound designed for advanced antibacterial studies. As an isotopically labeled analog of Levofloxacin, it offers enhanced stability and precise isotopic tracking. Levofloxacin-13C,d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel antibacterial therapies. Trusted by leading laboratories, Levofloxacin-13C,d3 is your go-to solution for cutting-edge antibacterial research. Unlock new possibilities in infection treatment with Levofloxacin-13C,d3, where innovation meets reliability.
| Catalog Number | S000241 |
| CAS Number | 1261398-33-7 |
| Molecular Formula | C1713CH17D3FN3O4 |
| Purity | 95% |
| IUPAC Name | (2S)-7-fluoro-2-methyl-10-oxo-6-[4-(trideuterio(113C)methyl)piperazin-1-yl]-4-oxa-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| InChI | InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1/i2+1D3 |
| InChIKey | GSDSWSVVBLHKDQ-BSEWDJTNSA-N |
| SMILES | [2H][13C]([2H])([2H])N1CCN(CC1)C2=C(C=C3C4=C2OC[C@@H](N4C=C(C3=O)C(=O)O)C)F |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86. [3]. Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014. [4]. Lee, B.T., et al., Efficacy of Levofloxacin in the Treatment of BK Viremia: A Multicenter, Double-Blinded, Randomized, Placebo-Controlled Trial. Clin J Am Soc Nephrol, 2014. |
